Previous Article | Next Article ![]()
Infect Immun, February 1998, p. 650-655, Vol. 66, No. 2
Department of
Pathology1 and
Division of Pulmonary and
Critical Care Medicine, Department of
Medicine,2 University of Michigan Medical
School, Ann Arbor, Michigan 48109
Received 29 July 1997/Returned for modification 30 September
1997/Accepted 20 November 1997
This study demonstrates that the therapeutic effect of a
nitric oxide inhibitor in a murine model of fecal
peritonitis is mediated in part by increased
levels of interleukin-10 (IL-10) and monocyte chemoattractant
protein 1 (MCP-1). Female CD1 mice were subjected to cecal
ligation and puncture (CLP) with a 21-gauge needle and, immediately
following surgery, were injected intraperitoneally with saline,
NG-nitro-L-arginine methyl
ester (L-NAME; 8 mg/kg), or
NG-nitro-D-arginine methyl ester
(D-NAME; 8 mg/kg). At 96 h after surgery and drug
treatment, 20% of mice that received D-NAME had survived
whereas 60% of mice that received L-NAME were alive. To
elucidate the effect of L-NAME treatment on chemokine and
cytokine production during fecal peritonitis, the levels
of macrophage inflammatory protein 2 (MIP-2), IL-10, and MCP-1 were
measured in peritoneal washings from additional groups of mice
24 h after the CLP surgery. Peritoneal fluids from
L-NAME-treated mice contained significantly higher levels
of IL-10 and MCP-1 than did those from D-NAME-treated mice.
To elucidate the effect of nitric oxide inhibition on potential
cellular sources of IL-10 and MCP-1 in the CLP model, cultured alveolar
and peritoneal macrophages were activated with bacterial
lipopolysaccharide in the presence of L-NAME; these
macrophages produced significantly more MCP-1 than did similarly
activated macrophages in the presence of D-NAME. In the CLP
surgery model, immunoneutralization of IL-10 alone or IL-10 and MCP-1
together with polyclonal antibodies prior to surgery significantly
reduced the survival rates in L-NAME-treated groups
compared with L-NAME-treated groups that received preimmune serum. Taken together, these data demonstrate that the inhibition of
nitric oxide following experimental CLP fecal peritonitis is therapeutic, in part through the modulatory effect of this treatment on
the synthesis of IL-10 and MCP-1.
0019-9567/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Therapeutic Effects of Nitric Oxide Inhibition during
Experimental Fecal Peritonitis: Role of Interleukin-10 and Monocyte
Chemoattractant Protein 1
*
Corresponding author. Mailing address: Department of
Pathology, University of Michigan Medical School, 1301 Catherine Rd., Ann Arbor, MI 48109. Phone: (313) 936-1020. Fax: (313) 764-2397. E-mail: hogaboam{at}path.med.umich.edu.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»